POST-TEST

5-Minute Journal Club: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 7

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **The Phase III EMBER-3 study evaluated which experimental treatment for patients with HR-positive, HER2-negative advanced breast cancer after disease progression on prior endocrine therapy?**
   a. Elacestrant monotherapy
   b. Elacestrant with abemaciclib
   c. Imlunestrant monotherapy
   d. Imlunestrant with abemaciclib
   e. Both a and b
   f. Both c and d

2. **What was the median progression-free survival (PFS) for patients who had previously received CDK4/6 inhibitor treatment and who received the combination regimen in the EMBER-3 study?**
   a. 2.1 months
   b. 3.7 months
   c. 6.0 months
   d. 9.1 months

3. **Which of the following best describes the study design of the SERENA-2 study?**
   a. Phase I study evaluating camizestrant monotherapy in ER-positive, HER2-negative, ESR1-mutant advanced breast cancer
   b. Phase II study evaluating different dose levels of camizestrant versus fulvestrant in ER-positive, HER2-negative advanced breast cancer
   c. Phase III study evaluating camizestrant versus fulvestrant in ER-positive, HER2-negative advanced breast cancer that previously received a CDK4/6 inhibitor

4. **Which of the following best describes the prevalence of ESR1 mutations in a real-world study in patients with HR-positive, HER2-negative metastatic breast cancer?**
   a. ESR1 mutations were the most prevalent in the first-line setting
   b. ESR1 mutations were the most prevalent in patients that previously received systemic therapy
   c. ESR1 mutations were equally prevalent in the first-line and later-line setting

5. **What was the investigator-assessed median progression-free survival (PFS) for patients with ER-positive, HER2-negative advanced breast cancer and an ESR1 mutation who received imlunestrant monotherapy in the Phase III EMBER-3 study?**
   a. 1.2 months
   b. 2.5 months
   c. 5.5 months
   d. 9.7 months